South Korean Won: Rangebound against US Dollar – Societe Generale
Societe Generale analysts observe that USD/KRW stalled after meeting interim resistance around 1561 in June and now looks set to trade within a range. They see limited evidence of a large decline, with 1530 as initial support on pullbacks. A break above 1561 would signal trend resumption, targeting projections near 1573/1580.
Watching 1561 and 1530 levels
"USD/KRW has encountered interim resistance around 1561 in June."
"The up move has stalled after this test, and the pair may evolve within a range."
"Signals of a large decline are not yet visible."
"If a short-term pullback develops, the recent pivot low of 1530 could be the first layer of support."
"A cross beyond 1561 may lead to a resumption of the uptrend."
"The next projections could be located at 1573/1580."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The "Outlier" Investment Art in the New Era of Berky
Chevron (CVX.US) explores alternative hedging for Middle East supply disruptions: targets Argentina and the Mediterranean to drive global LNG growth, seeks deal with India
Chevron is focusing on Argentina and the Mediterranean region, seeking global growth in liquefied natural gas, and plans to reach an agreement with India.
Energy and food price pressures intensify, potentially triggering an inflation rebound! The Bank of England may struggle to remain "calm" as market rate hike bets surge
The upward pressure on energy prices caused by the unresolved Middle East war is mounting. New risks are also approaching, which may keep inflation above the Bank of England’s 2% target for most of next year.
AstraZeneca (AZN.US) Breast Cancer Drug Etcamah Faces Setback in Phase III Clinical Trial, Potentially Impacting Billions in Sales
Bloomberg Intelligence analyst John Murphy stated that the setback in AstraZeneca's breast cancer drug trial could reduce sales in 2035 by $2.6 billion to $3.8 billion.
Crypto prices
More
